Management of pediatric low-grade glioma.

ABSTRACT:

Purpose of review

Pediatric low-grade gliomas (pLGGs) have been treated with similar therapies for the last 30 years. Recent biological insights have allowed a new generation of targeted therapies to be developed for these diverse tumors. At the same time, technological advances may redefine the late toxicities associated with radiation therapy. Understanding recent developments in pLGG therapy is essential to the management of these common pediatric tumors.

Recent findings

It is now well understood that aberrations of the mitogen-activated protein kinase pathway are key to oncogenesis in low-grade gliomas. This understanding, along with the development of available targeted agents, have heralded a new era of understanding and treatment for these patients. Promising, sustain

SUBMITTER: de Blank P 

PROVIDER: S-EPMC6664811 | biostudies-literature | 2019 Feb

REPOSITORIES: biostudies-literature